Sunho Park1, Seung-Jun Kim2, Donghyeon Yu3, Samuel Peña-Llopis4, Jianjiong Gao5, Jin Suk Park1, Beibei Chen1, Jessie Norris1, Xinlei Wang6, Min Chen7, Minsoo Kim1, Jeongsik Yong8, Zabi Wardak9, Kevin Choe9, Michael Story9, Timothy Starr10, Jae-Ho Cheong11, Tae Hyun Hwang12. 1. Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA. 2. Department of Computer Science and Electrical Engineering, University of Maryland at Baltimore County, Baltimore, MD, USA. 3. Department of Statistics, Keimyung University, Daegu, South Korea. 4. Internal Medicine and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. 5. Center for Molecular Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Statistical Science, Southern Methodist University, Dallas, TX, USA. 7. Department of Mathematical Sciences, University of Texas at Dallas, Dallas, TX, USA. 8. Department of Biochemistry, Molecular Biology and Biophysics, Obstetrics, Gynecology & Women's Health, University of Minnesota Twin Cities, Minneapolis, MN, USA. 9. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA, Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 10. Genetics, Cell Biology, University of Minnesota Twin Cities, Minneapolis, MN, USA, Masonic Cancer Center, University of Minnesota Twin Cities, Minneapolis, MN, USA. 11. Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea and Open NBI Convergence Technology Research Laboratory, Yonsei University College of Medicine, Seoul, South Korea. 12. Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Abstract
MOTIVATION: Identification of altered pathways that are clinically relevant across human cancers is a key challenge in cancer genomics. Precise identification and understanding of these altered pathways may provide novel insights into patient stratification, therapeutic strategies and the development of new drugs. However, a challenge remains in accurately identifying pathways altered by somatic mutations across human cancers, due to the diverse mutation spectrum. We developed an innovative approach to integrate somatic mutation data with gene networks and pathways, in order to identify pathways altered by somatic mutations across cancers. RESULTS: We applied our approach to The Cancer Genome Atlas (TCGA) dataset of somatic mutations in 4790 cancer patients with 19 different types of tumors. Our analysis identified cancer-type-specific altered pathways enriched with known cancer-relevant genes and targets of currently available drugs. To investigate the clinical significance of these altered pathways, we performed consensus clustering for patient stratification using member genes in the altered pathways coupled with gene expression datasets from 4870 patients from TCGA, and multiple independent cohorts confirmed that the altered pathways could be used to stratify patients into subgroups with significantly different clinical outcomes. Of particular significance, certain patient subpopulations with poor prognosis were identified because they had specific altered pathways for which there are available targeted therapies. These findings could be used to tailor and intensify therapy in these patients, for whom current therapy is suboptimal. AVAILABILITY AND IMPLEMENTATION: The code is available at: http://www.taehyunlab.org CONTACT: jhcheong@yuhs.ac or taehyun.hwang@utsouthwestern.edu or taehyun.cs@gmail.com SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
MOTIVATION: Identification of altered pathways that are clinically relevant across humancancers is a key challenge in cancer genomics. Precise identification and understanding of these altered pathways may provide novel insights into patient stratification, therapeutic strategies and the development of new drugs. However, a challenge remains in accurately identifying pathways altered by somatic mutations across humancancers, due to the diverse mutation spectrum. We developed an innovative approach to integrate somatic mutation data with gene networks and pathways, in order to identify pathways altered by somatic mutations across cancers. RESULTS: We applied our approach to The Cancer Genome Atlas (TCGA) dataset of somatic mutations in 4790 cancerpatients with 19 different types of tumors. Our analysis identified cancer-type-specific altered pathways enriched with known cancer-relevant genes and targets of currently available drugs. To investigate the clinical significance of these altered pathways, we performed consensus clustering for patient stratification using member genes in the altered pathways coupled with gene expression datasets from 4870 patients from TCGA, and multiple independent cohorts confirmed that the altered pathways could be used to stratify patients into subgroups with significantly different clinical outcomes. Of particular significance, certain patient subpopulations with poor prognosis were identified because they had specific altered pathways for which there are available targeted therapies. These findings could be used to tailor and intensify therapy in these patients, for whom current therapy is suboptimal. AVAILABILITY AND IMPLEMENTATION: The code is available at: http://www.taehyunlab.org CONTACT: jhcheong@yuhs.ac or taehyun.hwang@utsouthwestern.edu or taehyun.cs@gmail.com SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Samuel Peña-Llopis; Silvia Vega-Rubín-de-Celis; Arnold Liao; Nan Leng; Andrea Pavía-Jiménez; Shanshan Wang; Toshinari Yamasaki; Leah Zhrebker; Sharanya Sivanand; Patrick Spence; Lisa Kinch; Tina Hambuch; Suneer Jain; Yair Lotan; Vitaly Margulis; Arthur I Sagalowsky; Pia Banerji Summerour; Wareef Kabbani; S W Wendy Wong; Nick Grishin; Marc Laurent; Xian-Jin Xie; Christian D Haudenschild; Mark T Ross; David R Bentley; Payal Kapur; James Brugarolas Journal: Nat Genet Date: 2012-06-10 Impact factor: 38.330
Authors: Michael S Lawrence; Petar Stojanov; Craig H Mermel; James T Robinson; Levi A Garraway; Todd R Golub; Matthew Meyerson; Stacey B Gabriel; Eric S Lander; Gad Getz Journal: Nature Date: 2014-01-05 Impact factor: 49.962
Authors: Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell Journal: Nucleic Acids Res Date: 2014-10-29 Impact factor: 16.971
Authors: Jae-Ho Cheong; Sam C Wang; Sunho Park; Matthew R Porembka; Alana L Christie; Hyunki Kim; Hyo Song Kim; Hong Zhu; Woo Jin Hyung; Sung Hoon Noh; Bo Hu; Changjin Hong; John D Karalis; In-Ho Kim; Sung Hak Lee; Tae Hyun Hwang Journal: Nat Commun Date: 2022-02-09 Impact factor: 14.919